东诚药业：氟[18F]思睿肽注射液III期临床试验已完成488例受试者入组

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced that its subsidiary, Lannacheng, has completed the enrollment of all 488 participants in the Phase III clinical trial for the radiopharmaceutical Fluorine-18 [18F] PSMA peptide injection, which is intended for PET imaging in prostate cancer patients. This product currently has no domestic competitors, while similar products are available internationally [1]. Group 1 - The Phase III clinical trial for Fluorine-18 [18F] PSMA peptide injection has successfully enrolled 488 subjects [1]. - The drug targets PSMA and is designed for PET imaging in prostate cancer patients [1]. - There are currently no similar products available in the domestic market, while international competitors exist [1]. Group 2 - Lantheus's 2024 annual report indicates that its product, 18F-PSMA diagnostic PYLARIFY, is projected to achieve sales revenue of $1.1 billion in 2024 [1]. - The total research and development investment for the Fluorine-18 [18F] PSMA peptide injection project has reached approximately 119 million yuan [1].